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In most patients, pancreatic ductal adenocarcinoma
(PDAC) is metastatic at diagnosis and available systemic
therapies have had only a modest impact on survival
duration. The overwhelming majority of patients with
apparent localized, operable disease have extra-pancreatic
micrometastases. Cancer patients experience both sys-
temic and intra-tumor immune suppression. Thus, it is
likely that pancreatic tumors evade immune surveillance.
Harnessing the immune system to eradicate tumor cells
represents a logical treatment approach and the optimal
patient subset for study are those with operable disease.
The immune profile of pancreatic cancer patients, espe-
cially those receiving active treatment, has not been stu-
died. We are examining how neoadjuvant therapy affects
the immunity of PDAC patients with low tumor burden
and operable disease. We hypothesize that the changes in
the peripheral immune profile that occur during neoadju-
vant therapy will reflect host/tumor immunity, and that
these changes will be associated with tumor response/
relapse and patient survival. To address this hypothesis
we are examining immune profiles in peripheral blood
samples acquired before neoadjuvant therapy (baseline),
after neoadjuvant therapy (but before surgery), and again
after surgery. Our preliminary data shows that during
neoadjuvant therapy, there is a reduction in the percen-
tage of CD4 T cells and an increase in the percentage of
CD8 T cells. In some patients the CD8 T cells up-regu-
late the PD-1 and 2B4 inhibitory receptors (referred to as
immune checkpoint proteins). One interpretation of
these findings is that neoadjuvant therapy facilitates
immune activation. Patients that have increased expres-
sion of PD-1 and 2B4 on CD8 T cells may have more
activated adaptive immunity induced by neoadjuvant
therapy. Further patient follow-up will determine if this
profile correlates with a more favorable disease outcome.
Our preliminary data indicate that the neoadjuvant treat-
ment period may be an opportune time to add immune
therapy to release T cell immune suppression. We antici-
pate that our data will contribute to an understanding of
how the immune system is altered during PDAC progres-
sion and will provide a rationale for the timing and deliv-
ery of novel anti-tumor immunotherapies to improve
patient survival.
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